Clinical trial evaluation: the EDOSURE clinical trial program

References

• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–2104. doi:10.1056/nejmoa1310907
   PubMed Web of Science ®Google Scholar
• Büller H, Décousus H, Grosso M, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369:1406–1415. doi:10.1056/NEJMoa1306638
   PubMed Web of Science ®Google Scholar
• Goette A, Merino JL, Ezekowitz MD, et al. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, Phase IIIb trial. Lancet. 2016;388(10055):1995–2003. doi:10.1016/S0140-6736(16)31474-X
   PubMed Web of Science ®Google Scholar
• Hohnloser SH, Camm J, Cappato R, et al. Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial. Eur Heart J. 2019;40:3013–3021. doi:10.1093/eurheartj/ehz190
   PubMed Web of Science ®Google Scholar
• Vranckx P, Valgimigli M, Eckardt L, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, Phase IIIb trial. Lancet. 2019;394:1335–1343. doi:10.1016/S0140-6736(19)31872-0
   PubMed Web of Science ®Google Scholar
• Van Mieghem NM, Unverdorben M, Hengstenberg C, et al. Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR. N Engl J Med. 2021;385:2150–2160. doi:10.1056/NEJMoa2111016
   PubMed Web of Science ®Google Scholar
• Okumura K, Akao M, Yoshida T, et al. Low-dose edoxaban in very elderly patients with atrial fibrillation. N Engl J Med. 2020;383:1735–1745. doi:10.1056/NEJMoa2012883
   PubMed Web of Science ®Google Scholar
• Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378:615–624. doi:10.1056/NEJMoa1711948
   PubMed Web of Science ®Google Scholar
• Lee SL, Ong TJ, Mazlan-Kepli W, et al. Patients' time in therapeutic range on warfarin among atrial fibrillation patients in warfarin medication therapy adherence clinic. World J Cardiol. 2021;13(9):483–492. doi:10.4330/wjc.v13.i9.483
   PubMed Web of Science ®Google Scholar
• Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42:373–498. doi:10.1093/eurheartj/ehaa612
   PubMed Web of Science ®Google Scholar
• Hahn JY, Bin SY, Oh JH, et al. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. Lancet. 2018;391:1274–1284. doi:10.1016/S0140-6736(18)30493-8
   PubMed Web of Science ®Google Scholar
• Joosten LPT, van Doorn S, van de Ven PM, et al. Safety of switching from a vitamin K antagonist to a non-vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation: results of the FRAIL-AF randomized controlled trial. Circulation. 2023;149(4):279–289. doi:10.1161/CIRCULATIONAHA.123.066485
   PubMed Web of Science ®Google Scholar
• Li Z, Dawson E, Moodie J, et al. Frailty in patients undergoing transcatheter aortic valve implantation: a protocol for a systematic review. BMJ Open. 2019;9(2):e024163. doi:10.1136/bmjopen-2018-024163
   PubMed Web of Science ®Google Scholar
• Lee AYY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146–153. doi:10.1056/NEJMoa025313
   PubMed Web of Science ®Google Scholar
• Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36(20):2017–2023. doi:10.1200/JCO.2018.78.8034
   PubMed Web of Science ®Google Scholar
• Agnelli G, Becattini C, Meyer G, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020;382:1599–1607. doi:10.1056/NEJMoa1915103
   PubMed Web of Science ®Google Scholar
• Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020;38(5):496–520. doi:10.1200/JCO.19.01461
   PubMed Web of Science ®Google Scholar
• Ballestri S, Romagnoli E, Arioli D, et al. Risk and management of bleeding complications with direct oral anticoagulants in patients with atrial fibrillation and venous thromboembolism: a narrative review. Adv Therapy. 2022;40:41–66. doi:10.1007/s12325-022-02333-9
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Camm AJ, Goette A, et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. 2020;383:1305–1316. doi:10.1056/NEJMoa2019422
   PubMed Web of Science ®Google Scholar
• Sakamoto Y, Nishiyama Y, Iwasaki Y, et al. Design and rationale of the STroke secondary prevention with catheter ABLation and EDoxaban clinical trial in patients with non-valvular atrial fibrillation: the STABLED study. J Cardiol. 2019;74:539–542. doi:10.1016/j.jjcc.2019.06.002
   PubMed Web of Science ®Google Scholar
• Nielsen PB, Skjøth F, Søgaard M, et al. Non-vitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients with intracerebral hemorrhage. Stroke. 2019;50:939–946. doi:10.1161/STROKEAHA.118.023797
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Unverdorben M, Koretsune Y, et al. P4785 Clinical characteristics and 1-year outcomes in atrial fibrillation patients with or without history of intracranial haemorrhage treated with edoxaban: snapshot analysis of the Global ETNA-AF program. Eur Heart J. 2019;40(Suppl. 1). doi:10.1093/eurheartj/ehz745.1161
   Google Scholar